LexaGene (OTC: LXXGF / CN: LXG)
The commercial food industry has a $77 billion headache,
and these three innovative companies are close to a cure.
The headlines are shocking— 5 dead from eating e. Coli-tainted romaine, 197 sickened, 89 hospitalized[i], 26 cases of kidney failure.[ii] Even before the lettuce outbreak ended, came the news that 10 children were sickened by drinking raw milk—four of them lingering in intensive care.[iii]
The pace and spread of these outbreaks is getting worse thanks to how far from the farm a simple product like lettuce can travel in the modern grocery business. The tainted romaine grown in Arizona made people sick in faraway Georgia, Connecticut, Missouri. [iv]In just the two months of April and May this year, the FDA issued 38 food recalls[v].
The problems seem unavoidable, even by the most careful shoppers… listeria in mini éclairs… salmonella in organic coconut flour[vi]… listeria in frozen broccoli…salmonella in tilapia…botulism in smoked salmon… salmonella in eggs and tahini[vii]…. And by the time the first case is reported and diagnosed, millions of others have usually already eaten the same tainted food.
The food industry is reeling and looking for answers.
These three companies—Thermo Fisher Scientific, Biomerieux, and LexaGene—are close. And the first one to go widespread with their solution could make investors fortunes in the already-hot medical device market.
Three Respected, Brilliant Companies Race for the Answer— One of Them Is Ready to Take the Lead
One answer could come from Thermo Fisher Scientific (Nasdaq: TMO). Its RapidFinder STEC system can diagnose E. coli and several other pathogens in food and beverages within 12 hours. But RapidFinder has been around for six years[x] and takes substantial training to use. That holds it back.
That’s why we think Biomerieux (Eurostock: BIM) is more exciting. BIM’s GENE-UP system can analyze a food or beverage sample within 8-24 hours[xi]. Another device, the BioFire can identify the exact bacteria, virus, or fungus causing a patient’s illness within one hour. Unfortunately you have to buy shares in Europe, because its US ADR rarely trades.
But LexaGene (OTC: LXXGF / CN: LXG) is the dark horse that appears poised to unleash a system that could rapidly dominate the situation. LexaGene’s trailblazing LX-6 is compact, fast, reliable, and easy to run—no biotech degree or medical license required! And it does the same work as BOTH Biomerieux devices in one compact machine and returns results in less than an hour.
LexaGene’s capabilities are so exciting, that Ed Begley Jr. did an extended feature on the company on his popular NPR Innovations program.
LexaGene’s One-Hour Answers Are Poised to Save the Food Industry Billions in Lawsuits, Product Recalls, and Lost Sales
We tend to focus on the consumers who get sick, but pathogens in food have serious economic repercussions. That’s why we think LexaGene’s compact, easy-to-use, affordable, and highly accurate LX-6 bioassay system will be welcomed in the food industry.
Tainted food is truly a big problem the grocery industry understands all too well. The Grocery Managers Association estimates the average cost of a food recall at $10 million[xii]. But when they polled industry executives, more than half estimated a Class I food recall cost their company more than that—about 5% had experienced losses of more than $100 million.[xiii]
LexaGene (OTC: LXXGF / CN: LXG) is new as a medical device market brand, but it has deep roots and serious allies in the business. CEO, leader, and inventor Dr. Jack Regan has successfully led teams developing bioassay devices and support at Bio-Rad, Quanta Life, and Applied Biosystems.[xiv] But the LX-6 comes from his work at the esteemed Lawrence Livermore National Laboratory.
Through a $20 million grant, Lawrence Livermore funded the initial work and previous prototypes—one of which was built to detect bio-warfare agents after 9/11 and became part of the Department of Homeland Security’s BioWatch Program. Another prototype leading to LexaGene’s LX-6 was used to rapidly detect respiratory pathogens, such as influenza and RSV.
Now, LexaGene’s fourth-generation instrument is near commercialization.
And not a moment too soon, considering the massive industry impact the Food Safety Modernization Act is already having. We predict the industry will quickly take note and look to LexaGene’s LX-6 to solve our $77 billion tainted food problem.
LexaGene founder, Dr. Jack Regan, clearly explains the dilemma facing the commercial food industry in an article he wrote for Food and Quality Safety magazine:
“The Food Safety Modernization Act rules and regulations now require food producers to perform pathogen testing to minimize the probability of recalls. Although there is a willingness to perform pathogen testing, food producers don’t want to excessively pay for testing, as it bites into their bottom line. Hence, food safety testing programs are all about sufficiently managing risk, while preserving the bottom line.”
That is a major advantage for LexaGene. The affordable LX-6 can be operated onsite by any responsible employee. There’s no need to hire a consultant for batch testing or employ a trained biotechnician.
And because the LX-6 works so rapidly, it can alert companies to potential problems before incurring the high costs of a recall… without interrupting or slowing down the work flow.
So Many Reasons to Admire LexaGene (OTC: LXXGF / CN: LXG)
Top Professional Connections—In addition to Lawrence Livermore and Boston Engineering LexaGene has an agreement with the Stanford University School of Medicine to incorporate cancer-sequencing technology into the LX-6 for medical diagnostics. And Texas A&M Veterinary School is testing the LX-6 for effectiveness in identifying pathogens in dog urine—a quick response answer that could replace current tests that take days.
Commercialization in 2019—Extensive testing has shown outstanding results. LexaGene expects it will beat its goal to get the LX-6 on the market by 2019.
Big Incentive for Buyers—The LX-6 Fits Their World—Because regular company personnel can operate the LX-6, there’s no need for a trained lab technician. The machine makes it easy.
Fast, Accurate Results from Simple Prep—A tiny liquid sample, swab, or water used to wash produce will suffice. The LX-6 gives companies results within one hour. This can stop E. coli and other pathogenic outbreaks at the farm and factory, before anyone suffers.
Multiplex Covers More Angles—Multiplex means that the machine can test for more than one pathogen from the same sample at the same time. It increases usefulness, cuts costs, saves times and makes identification of problems much more sure.
Rich in Potential—The $13.5 billion food safety industry is just one potential user for the LX-6. Vet practices ($4.2 billion) are also a lucrative market in need of this affordable, rapid, in-office diagnostic system. The human clinical market is another $18.2 billion target. Water safety $3.5 billion and aquaculture $3 billion. LexaGene already has bioassay materials ready to address all of them.
Put LexaGene (OTC: LXXGF / CN: LXG) On Your Watchlist
With commercialization happening soon, we predict LexaGene will soon stand out as one of 2018’s best stock market successes. Check out their site and see for yourself the massive opportunity that is emerging.
 http://fortune.com/food-contamination/ text box quote article May 2016
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.